Sarcio is developing an allogenic, injectable therapy using induced pluripotent stem cell (iPSC)-derived hyaline cartilage cells to restore joint function in patients with osteoarthritis. This approach aims to delay or prevent the need for joint replacement by addressing cartilage degradation and inflammation.
Funding
Funding not disclosed
Founders
Product
Problem
Osteoarthritis patients face limited long-term solutions beyond temporary treatments like physical therapy and injections, often leading to joint replacement surgery. Joint replacements have long recovery times and limited lifespans, potentially requiring multiple surgeries on the same joint.
Solution
Sarcio is developing an allogeneic, injectable cell therapy using induced pluripotent stem cell (iPSC)-derived hyaline cartilage cells to regenerate and restore joint function in osteoarthritis patients. This off-the-shelf therapy aims to address cartilage degradation and reduce inflammation, potentially delaying or preventing the need for joint replacement. The therapy is designed to reach patients early in the disease progression to restore joint function, enabling pain-free movement.
Target Audience
The primary target audience includes osteoarthritis patients seeking alternatives to joint replacement and clinicians specializing in orthopedic care and regenerative medicine.
Features
- Allogeneic, off-the-shelf injectable formulation for ease of administration.
- iPSC-derived hyaline cartilage cells promote cartilage regeneration and repair.
- Designed to reduce inflammation within the affected joint.
- Aims to restore normal joint function and mobility.